AVXL - AVXL ALERT: Bragar Eagel & Squire P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Anavex Life Sciences Corp. (NASDAQ:AVXL) on behalf of long-term stockholders following a class action complaint that was filed against AVXL on March 13, 2024 with a Class Period from June 21, 2021 to January 1, 2024. Our investigation concerns whether the board of directors of AVXL have breached their fiduciary duties to the company.
The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's ...